» Articles » PMID: 24461332

Eosinophilic Oesophagitis and Proton Pump Inhibitor-responsive Oesophageal Eosinophilia Have Similar Clinical, Endoscopic and Histological Findings

Overview
Date 2014 Jan 28
PMID 24461332
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Some patients with a phenotypic appearance of eosinophilic oesophagitis (EoE) respond histologically to PPI, and are described as having PPI-responsive oesophageal eosinophilia (PPI-REE). It is unclear if PPI-REE is a GERD-related phenomenon, a subtype of EoE, or a completely unique entity.

Aim: To compare demographic, clinical and histological features of EoE and PPI-REE.

Methods: Two databases were reviewed from the Walter Reed and Swiss EoE databases. Patients were stratified into two groups, EoE and PPI-REE, based on recent EoE consensus guidelines. Response to PPI was defined as achieving less than 15 eos/hpf and a 50% decrease from baseline following at least a 6-week course of treatment.

Results: One hundred and three patients were identified (63 EoE and 40 PPI-REE; mean age 40.2 years, 75% male and 89% Caucasian). The two cohorts had similar dysphagia (97% vs. 100%, P = 0.520), food impaction (43% vs. 35%, P = 0.536), and heartburn (33% vs. 32%, P = 1.000) and a similar duration of symptoms (6.0 years vs. 5.8 years, P = 0.850). Endoscopic features were also similar between EoE and PPI-REE; rings (68% vs. 68%, P = 1.000), furrows (70% vs. 70%, P = 1.000), plaques (19% vs. 10%, P = 0.272), strictures (49% vs. 30%, P = 0.066). EoE and PPI-REE were similar in the number of proximal (39 eos/hpf vs. 38 eos/hpf, P = 0.919) and distal eosinophils (50 vs. 43 eos/hpf, P = 0.285).

Conclusions: EoE and PPI-responsive oesophageal eosinophilia are similar in clinical, histological and endoscopic features and therefore are indistinguishable without a PPI trial. Further studies are needed to determine why a subset of patients with oesophageal eosinophilia respond to PPI.

Citing Articles

Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics.

Rodriguez-Alcolado L, Navarro P, Arias-Gonzalez L, Grueso-Navarro E, Lucendo A, Laserna-Mendieta E Pharmaceutics. 2024; 16(4).

PMID: 38675148 PMC: 11054109. DOI: 10.3390/pharmaceutics16040487.


High prevalence of response to PPI treatment in children and adolescents with eosinophilic esophagitis in southern Brazil.

Nader L, Epifanio M, Coelho M, Steinhaus C, Melere M, da Silva C Front Allergy. 2024; 5:1346843.

PMID: 38650863 PMC: 11033356. DOI: 10.3389/falgy.2024.1346843.


Benralizumab treatment in an elderly patient with eosinophilic esophagitis resulted in remission: a case report.

Ishii A, Shibata T, Tsunoda Y, Kayukawa T, Kobayashi M, Orinaka M BMC Geriatr. 2024; 24(1):92.

PMID: 38267847 PMC: 10809539. DOI: 10.1186/s12877-024-04683-1.


Eosinophilic esophagitis: Immune mechanisms and therapeutic targets.

Khokhar D, Marella S, Idelman G, Chang J, Chehade M, Hogan S Clin Exp Allergy. 2022; 52(10):1142-1156.

PMID: 35778876 PMC: 9547832. DOI: 10.1111/cea.14196.


Histological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: A case report.

Huguenot M, Bruhm A, Essig M World J Clin Cases. 2022; 10(14):4502-4508.

PMID: 35663093 PMC: 9125258. DOI: 10.12998/wjcc.v10.i14.4502.